Business Description
MiNK Therapeutics Inc
NAICS : 541714
SIC : 2836
ISIN : US6036932019
Total Employee Number:
15Description
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States that develops allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its lead product candidate, agenT-797, is an allogeneic native iNKT cell therapy being studied in solid tumors and other indications, with additional programs including engineered iNKT cell therapies and related assets. The company's platform is designed to leverage iNKT cells' ability to home to tissues, help clear tumor and infected cells, and modulate immune responses. MiNK Therapeutics operates as a single reporting segment, funding its activities primarily through equity financings, collaborations, and licensing arrangements, and it generates no product revenue at its current clinical stage.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.7 | |||||
Equity-to-Asset | -1.46 | |||||
Debt-to-Equity | -0.37 | |||||
Debt-to-EBITDA | -0.42 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32 | |||||
3-Year EPS without NRI Growth Rate | 29.6 | |||||
3-Year FCF Growth Rate | 37.5 | |||||
3-Year Book Growth Rate | -194.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.51 | |||||
9-Day RSI | 53.11 | |||||
14-Day RSI | 52.94 | |||||
3-1 Month Momentum % | -10.36 | |||||
6-1 Month Momentum % | 6.79 | |||||
12-1 Month Momentum % | -61.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 1.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -7.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -109.91 | |||||
ROIC % | -196.35 | |||||
3-Year ROIIC % | 390.32 | |||||
ROC (Joel Greenblatt) % | -3144.96 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -4.29 | |||||
EV-to-Forward-EBIT | -3.01 | |||||
EV-to-EBITDA | -4.33 | |||||
EV-to-Forward-Revenue | 13.1 | |||||
EV-to-FCF | -7.77 | |||||
Earnings Yield (Greenblatt) % | -23.32 | |||||
FCF Yield % | -11.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MiNK Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.055 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 65.55 | ||
| 14-Day RSI | 52.94 | ||
| 14-Day ATR (€) | 0.924223 | ||
| 20-Day SMA (€) | 9.145 | ||
| 12-1 Month Momentum % | -61.04 | ||
| 52-Week Range (€) | 6.6 - 22.2 | ||
| Shares Outstanding (Mil) | 5.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MiNK Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MiNK Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 53 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 52 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:30 | 9.75 (+3.17%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 9.75 (+3.17%) | ||
| General meeting for 2026 | 2026-06-17 09:30 | 9.85 (+2.07%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | 8.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 8.40 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 08:30 | 9.05 (+5.85%) | ||
| Annual report for 2025 | 2026-03-31 | 9.05 (+5.85%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 9.05 (+5.85%) |
Show
Entries
MiNK Therapeutics Inc Frequently Asked Questions
What is MiNK Therapeutics Inc(FRA:6Q40)'s stock price today?
The current price of FRA:6Q40 is €9.55. The 52 week high of FRA:6Q40 is €22.20 and 52 week low is €6.60.
When is next earnings date of MiNK Therapeutics Inc(FRA:6Q40)?
The next earnings date of MiNK Therapeutics Inc(FRA:6Q40) is 2026-11-13 Est..
Does MiNK Therapeutics Inc(FRA:6Q40) pay dividends? If so, how much?
MiNK Therapeutics Inc(FRA:6Q40) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers